Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -0.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.69% |
| Mar 31, 2026 | 166.91% |
| Dec 31, 2025 | 90.54% |
| Sep 30, 2025 | 20.25% |
| Jun 30, 2025 | 52.83% |
| Mar 31, 2025 | -54.58% |
| Dec 31, 2024 | 68.25% |
| Sep 30, 2024 | -24.26% |
| Jun 30, 2024 | -59.59% |
| Mar 31, 2024 | 194.67% |
| Dec 31, 2023 | -22.36% |
| Sep 30, 2023 | 149.29% |
| Jun 30, 2023 | 28.14% |
| Mar 31, 2023 | -190.53% |
| Dec 31, 2022 | 3,440.43% |
| Sep 30, 2022 | 71.72% |
| Jun 30, 2022 | 38.48% |
| Mar 31, 2022 | -149.66% |
| Dec 31, 2021 | -105.55% |
| Sep 30, 2021 | 340.29% |